Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Hourglass and stock price chart
Energy Stocks

Two High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These companies have increased their dividends annually for decades.

Read more »

Piggy bank and Canadian coins
Dividend Stocks

Canadians: Here’s How Much You Need in Your TFSA to Retire

If you hold Fortis Inc (TSX:FTS) stock in a TFSA, you might earn enough dividends to cover part of your…

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

TFSA Season is Here: Canadian Stocks Worth Holding Tax-Free All Year

Investors should focus on total returns in their TFSA whether their focus is on income, growth, or a combination of…

Read more »

Nuclear power station cooling tower
Metals and Mining Stocks

How to Invest in Uranium as a Canadian in 2026

This ETF provides exposure to spot uranium prices and uranium miners.

Read more »

Oil industry worker works in oilfield
Energy Stocks

Canadian Investors: Should You Buy Canadian Natural Resources Stock While Under $45?

Is the Venezuela scare a threat or an opportunity? Here is why Canadian Natural Resources (TSX:CNQ) stock looks like a…

Read more »

Child measures his height on wall. He is growing taller.
Investing

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Agnico Eagle Mines (TSX:AEM) and another Canadian stock worth buying right here.

Read more »

e-commerce shopping getting a package
Tech Stocks

2 Laggards With High Upside Potential on the TSX Today

Given their long-term growth opportunities and discounted valuation, these two underperforming TSX stocks can deliver superior returns.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

1 Ideal TFSA Stock Paying 7% Income Every Month

A TFSA can feel like payday with a monthly payer like SmartCentres, but the real “winner” test is cash flow…

Read more »